Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Montelukast Sodium
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
IntelGenx Doses First Parkinson’s Patients with Montelukast VersaFilm in Phase 2 Trial
Details : Montelukast VersaFilm (montelukast) is a leukotriene receptor antagonist, which is being evaluated in patients with Parkinson’s Disease, the second most common neurodegenerative disease.
Product Name : Montelukast VersaFilm
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 04, 2024
Lead Product(s) : Montelukast Sodium
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Montelukast Sodium
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
IntelGenx Reports Preliminary Results for Montelukast VersaFilm® in Alzheimer’s Disease
Details : Montelukast VersaFilm (montelukast) is a small molecule CysLT1 receptor inhibitor, given in the form of buccal film, is currently being ivestigated for patients with alzheimer's disease.
Product Name : Montelukast VersaFilm
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 07, 2024
Lead Product(s) : Montelukast Sodium
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Montelukast Sodium
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : VersaFilm® (montelukast) is a leukotriene receptor antagonist, which is completed patient enrollment in the ongoing Phase 2a clinical trial in patients with mild to moderate Alzheimer’s Disease.
Product Name : Montelukast VersaFilm
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 14, 2023
Lead Product(s) : Montelukast Sodium
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Montelukast Sodium
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Karolinska Institute
Deal Size : $2.0 million
Deal Type : Collaboration
Details : Upon completion of the Study, IntelGenx will retain the intellectual property rights and use the findings to further develop its Montelukast VersaFilm® program for Parkinson's disease treatment.
Product Name : Montelukast VersaFilm
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
September 02, 2023
Lead Product(s) : Montelukast Sodium
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Karolinska Institute
Deal Size : $2.0 million
Deal Type : Collaboration
Lead Product(s) : Montelukast Sodium
Therapeutic Area : Neurology
Study Phase : IND Enabling
Sponsor : Karolinska University Hospital
Deal Size : $2.0 million
Deal Type : Agreement
Details : The agreement aims to investigate the use of IntelGenx’s Montelukast VersaFilm, a leukotriene receptor antagonist, for the treatment of Parkinson’s Disease.
Product Name : Montelukast VersaFilm
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 25, 2023
Lead Product(s) : Montelukast Sodium
Therapeutic Area : Neurology
Highest Development Status : IND Enabling
Sponsor : Karolinska University Hospital
Deal Size : $2.0 million
Deal Type : Agreement
Lead Product(s) : Montelukast Sodium
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : VersaFilm® (montelukast) is a leukotriene receptor antagonist, which is completed patient enrollment in the ongoing Phase 2a clinical trial in patients with mild to moderate Alzheimer’s Disease.
Product Name : Montelukast VersaFilm
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 08, 2023
Lead Product(s) : Montelukast Sodium
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Montelukast Sodium
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Resumption of patient dosing in the ongoing Phase 2a (BUENA) clinical trial of Montelukast VersaFilm, a leukotriene receptor antagonist on the basis of Phase 1 study data that reduces the first-pass-effect and has a 52% higher bioavailability.
Product Name : Montelukast VersaFilm
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 20, 2022
Lead Product(s) : Montelukast Sodium
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Montelukast Sodium
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : In Phase 1 studies, an oral film formulation of Montelukast is safe and tolerable in healthy subjects, reduces the first-pass-effect and has a 52% higher bioavailability compared to the Montelukast tablet, demonstrating a clear advantage of delivering Mo...
Product Name : Montelukast VersaFilm
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 10, 2021
Lead Product(s) : Montelukast Sodium
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Montelukast Sodium
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
IntelGenx Announces Publication of a Study Evaluating Montelukast’s Effect on Neurological Aging
Details : Data suggest Montelukast may inhibit mental decline, higher doses optimal for clinical trials assessing impact on neurological disease.
Product Name : Montelukast VersaFilm
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 11, 2020
Lead Product(s) : Montelukast Sodium
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Zileuton,Montelukast Sodium
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Novateur Study Points Toward Potential COVID-19 Treatment
Details : Novateur proposes a simple treatment paradigm using a combination of a leukotriene biosynthesis blocker, Zyflo® controlled release formulation and an inhibitor of the cysteinyl leukotriene 1 receptor, Singulair® to target the hyper-inflammatory respons...
Product Name : Zyflo
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 08, 2020
Lead Product(s) : Zileuton,Montelukast Sodium
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable